Pharmaceuticals

CF PharmTech, Inc. Closes a US $50M Series F Financing to Accelerate the Commercialization of its Inhalation Products.

SUZHOU, China, July 2, 2020 /PRNewswire/ -- CF PharmTech, Inc. ("CF PharmTech") announced today that it has raised US $50M in Series F financing following its US$90M Series E financing in January of 2020, in total, successfully completing an equity investment deal of nearly US$140M within six mon...

2020-07-02 09:00 1609

A RhoVac Article is Published in the June Edition of MedNous, a Publication of Evernow Publishing Ltd

STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac")  is published in the June edition of MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in RhoVac's achievements as well as plans for t...

2020-07-01 20:41 739

Yiling Pharmaceutical Lianhua Qingwen Capsule Extends Overseas Footprint in Southeast Asia

SHIJIAZHUANG, China, July 1, 2020 /PRNewswire/ -- Following Thailand, Singapore andIndonesia, Yiling Pharmaceutical (002603.SZ), a leader in the development of traditional Chinese medicines (TCM), obtained a Certificate of Registration issued by the Drug Department ofLaos' Ministry of Health whic...

2020-07-01 20:33 4015

RhoVac Marketed in International Press

STOCKHOLM, July 1, 2020 /PRNewswire/ -- RhoVac AB ("RhoVac") is marketed in the latest edition of the international trade press outlet, MedNous, through a written commentary by CEOAnders Månsson. In order to further attract the attention of potential partners and increase their interest in Rh...

2020-07-01 15:49 552

Clarivate Introduces Next Generation Insights Platform with Cortellis Generics Intelligence

LONDON, July 1, 2020 /PRNewswire/ -- Clarivate Plc (NYSE:CCC), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the launch ofCortellis Generics Intelligence™ to enable generics companies and Active Pharmaceutical Ingredient (API) ...

2020-07-01 15:00 4187

Lipidor AB (publ) Formalizes Relationship With Subsidiary Emollivet AB Through License Agreement and Proposes Financing of Subsidiary

STOCKHOLM, Sweden, July 1, 2020 /PRNewswire/ -- Lipidor AB ("Lipidor" or the " Company") and its subsidiary Emollivet AB ("Emollivet") have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor's patented AKVANO® technology. OnJune 30, Emollivet's Ext...

2020-07-01 08:06 599

FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma

DARMSTADT, Germany and NEW YORK, July 1, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with...

2020-07-01 07:30 4534

Carmine Therapeutics and Takeda Collaborate to Discover and Develop Rare Disease Gene Therapies Using Novel Red Blood Cell Extracellular Vesicles Platform

CAMBRIDGE, Mass., July 1, 2020 /PRNewswire/ -- Carmine Therapeutics announced today that it has signed a research collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targ...

2020-07-01 07:00 561

AGC Biologics Expands Development Capacities for pDNA Services at Heidelberg Site

Expansion will help meet the growing demand for plasmid DNA offerings SEATTLE, June 30, 2020 /PRNewswire/ -- Committed to continuous innovation and expansion of its service offerings, AGC Biologics has announced the expansion of its pDNA Center of Excellence in Heidelberg, Germany. The global bi...

2020-06-30 21:00 603

Release of Initial Attana Virus Analytics-AVA Testing Protocols

STOCKHOLM, June 30, 2020 /PRNewswire/ -- Attana has today released the initial technical protocols for AVA Antibody Testing and will make these available to all existing Attana customers. In close collaboration with Linnaeus University Attana application specialists have been performing studies ...

2020-06-30 15:42 439

Thrombosis Research Institute (TRI) Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19

- Clinical trial will recruit approximately 1400 patients in 10 countries starting in July  - Participants will be randomised to receive the low molecular weight Heparin enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis  - The study is supported through an inve...

2020-06-30 14:00 496

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

AOBiome's 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Massachusetts, June 30, 2020 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation,  announced initiation of a Phase2b clinical trial in pruritus (i...

2020-06-30 13:00 460

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent ...

2020-06-30 08:00 542

Qiming's Portfolio Company Gan & Lee Pharmaceuticals Lands A-Shares Main Board

SHANGHAI, June 29, 2020 /PRNewswire/ -- Chinese insulin manufacturer Gan & Lee Pharmaceuticals (SHSE: 603087), Qiming's portfolio company today lands on the A-shares main board market. The issue price of Gan & Lee isRMB 63.32 per share. The stock opens atRMB 91.18 per share, up 44%, with a market...

2020-06-29 11:31 717

Loss of Function Variant in FLT3 Strongly Increases the Risk of Autoimmune Thyroid Disease and Other Autoimmune Diseases

The combination of genomics, transcriptomics and proteomics sheds light on autoimmune thyroid disease, other autoimmune diseases and AML REYKJAVIK, Iceland, June 24, 2020 /PRNewswire/ -- Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare s...

2020-06-24 23:00 1336

Global Fund COVID-19 Report: Deaths from HIV, TB and Malaria Could Almost Double in 12 Months Unless Urgent Action is Taken

GENEVA, June 24, 2020 /PRNewswire/ -- A new report released by the Global Fund today estimates that countries affected by HIV, tuberculosis and malaria urgently needUS$28.5 billion to protect the extraordinary progress achieved in the fight against the three diseases in the past two decades. The...

2020-06-24 16:31 693

Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee

LOS ANGELES, June 24, 2020 /PRNewswire/ -- Akeso, Inc. ("Akeso", 9926.HK) announced the appointment of ProfessorBradley J. Monk, MD, FACOG[1], FACS[2] as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee for its global Phase 2, multicentre registration study to evaluate the ef...

2020-06-24 12:55 5557

InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition" at 2020 AACR Annual Meeting

SHANGHAI, June 24, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has released the research data of "FAK inhibitor IN10018...

2020-06-24 08:41 291

IgNova Files Patent Application on Antibody Against COVID-19

VISBEK, Germany, June 24, 2020 /PRNewswire/ -- IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (I...

2020-06-24 02:13 726

ABM Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ABM-1310 in the USA

SAN DIEGO, June 22, 2020 /PRNewswire/ -- ABM Therapeutics, a clinical-stage biopharmaceutical company developing a new generation of BRAF inhibitor, today announced that the first cancer patient has been successfully enrolled and dosed with ABM-1310 in the Phase 1 clinical trial in theUSA. ABM-13...

2020-06-22 23:00 506
12345 ... 77